Lineage Cell Therapeutics : Leading clinical-stage cell therapy company with in-house manufacturing capabilities and clinically validated technology. Innovative programs based on one of the largest and most comprehensive patent estates in cell therapy. 3 clinical programs in markets with billion dollar opportunities: 1) OpRegen, an RPE transplant therapy in Phase 1/2a development for the treatment of dry-AMD. Positive clinical results reported in first 16 enrolled patients, study expected to complete enrollment in Q1 2020 with an innovative delivery device from Orbit Biomedical Ltd.; 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. Positive clinical results reported from ongoing Phase 1/2a study for treatment of acute SCI. Program focus in 2020 are manufacturing enhancements and meeting with FDA to prepare for the next study; 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 for NSCLC conducted by CRUK. Company is also evaluating partnership opportunities to commercialize Renevia, a proprietary 3-D scaffold designed to support adipose tissue transplant and retention and which received a CE Mark in September 2019 for use in adults for the treatment of facial lipoatrophy.
Based in...
US - Pacific
Disease Space
Public, USA
Market Cap
100MM - 500MM
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
United States

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Brian Culley
Lineage Cell Therapeutics, CEO
Mr. Culley joined BioTime as CEO in September 2018. Prior to joining BioTime, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Lineage Cell Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Broadwood Capital, Inc. 22.72 34,005,379 30.96 13F 2020-03-31
Greenway Partners LP 4.43 6,635,973 6.04 Stakes 2019-12-31
The Vanguard Group, Inc. 3.67 5,490,090 5.00 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 3.58 5,361,191 4.88 13F 2020-03-31
Defender Capital LLC 2.95 4,416,590 4.02 13F 2020-03-31
BlackRock Fund Advisors 2.61 3,901,799 3.55 13F 2020-03-31
BlackRock Institutional Trust Co. NA 1.82 2,724,147 2.48 13F 2020-03-31
Prescott General Partners LLC 1.24 1,851,851 1.69 13F 2020-03-31
State Street Corp. 1.17 1,753,991 1.60 13F 2020-03-31
Geode Capital Management LLC 1.12 1,677,519 1.53 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.